Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 3/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 3/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301927 | 0.97 | RARB (0.37) | CNR2S1PR1CTSLCTSSCTSK | |
| SCHEMBL10301930 | 0.95 | RARB (0.39) | CNR2S1PR1CTSLCTSSCTSK | |
| SCHEMBL12740105 | 0.92 | FFAR4 (0.38) | CNR2S1PR1CTSLCTSSCTSK | |
| SCHEMBL12735572 | 0.92 | FFAR4 (0.38) | CNR2S1PR1CTSLCTSSCTSK | |
| SCHEMBL21869910 | 0.92 | CNR2 (0.39) | CNR2S1PR1CTSLCTSSCTSK | |
| SCHEMBL14766029 | 0.91 | CYP3A4 (0.40) | CNR2S1PR1CTSLCTSSCTSK | |
| SCHEMBL14766518 | 0.91 | CYP3A4 (0.40) | CNR2S1PR1CTSLCTSSCTSK | |
| SCHEMBL10301566 | 0.90 | FFAR4 (0.36) | S1PR1CTSLCTSSCTSKS1PR3 | |
| SCHEMBL14766907 | 0.88 | LMNA (0.39) | CNR2S1PR1CTSLCTSSCTSK | |
| SCHEMBL12735579 | 0.88 | MAPT (0.40) | CNR2S1PR1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | CNR2 2145/4885S1PR1 1915/4885CTSL 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.